Clinical Trial Update: Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating a regimen of decitabine, cytarabine, and arsenic trioxide for acute myeloid leukemia with p53 mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• decitabine, cytarabine and arsenic trioxide

Snippet

Sponsor: Li Junmin | Conditions: Acute Myeloid Leukemia, P53 Mutation | Phase 2 | Status: UNKNOWN